Government to invest over £133m in new tech to tackle cancer and debilitating illnesses

Economy & Politics | Funding | Healthcare | South East

People across the country could lead healthier and longer lives following significant government investment in new research to improve treatment, diagnosis and care options for devastating diseases including cancer.

The government has today unveiled details of how it will help thousands of people across the country living with debilitating, painful and/or sometimes life-threatening diseases by investing £133m in life-changing treatments for arthritis and cancer and for pioneering gene-based therapies for diseases including dementia and Parkinson’s.

Faster, more accurate diagnosis, and earlier interventions will be boosted by £50m to be pumped into NHS diagnostic services and support the work of existing Centres of Excellence in digital pathology and imaging with artificial intelligence. The centres – based in Leeds, Oxford, Coventry and London – will be able to partner with more NHS Trusts and further develop cutting edge products using digital systems and artificial intelligence that could ultimately save lives.

Adult social care will also receive a new cash injection of £7.5m to use research to improve care delivery for some of the most vulnerable people in our society and £14m for bioscience projects and technologies across the UK that could, for example, treat osteoarthritis and develop new vaccines.

Business Secretary Andrea Leadsom said: “Chronic and painful illnesses like arthritis and Parkinson’s are dreadful and prevent people from living a full life.

“Curing these kinds of debilitating illnesses is one of the great challenges we face globally, and today’s commitment will play a vital role in ensuring that our scientists and thinkers have the tools they need to find new treatments that will support people to lead longer, healthier lives.”

Did you enjoy reading this content?  To get more great content like this subscribe to our magazine

Reader's Comments

Comments related to the current article

Leave a comment

Your email address will not be published. Required fields are marked *